- 1.
Lu AY. Multiplicity of liver drug metabolizing enzymes. Drug Metab Rev 1979; 10: 187–208. [PubMed][CrossRef]
- 2.
Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651–62. [PubMed]
- 3.
Johnson JA. Use of pharmacogenetics in clinical medicine: hype or hope? Per Med 2005; 2: 279–82. [PubMed][CrossRef]
- 4.
Caudle KE, Klein TE, Hoffman JM et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab 2014; 15: 209–17. [PubMed][CrossRef]
- 5.
Hicks JK, Bishop JR, Sangkuhl K et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther 2015; 98: 127–34. [PubMed][CrossRef]
- 6.
Swen JJ, Nijenhuis M, de Boer A et al. Pharmacogenetics: from bench to byte–an update of guidelines. Clin Pharmacol Ther 2011; 89: 662–73. [PubMed][CrossRef]
- 7.
Crews KR, Gaedigk A, Dunnenberger HM et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 2012; 91: 321–6. [PubMed][CrossRef]
- 8.
Reseptregisteret. http://www.reseptregisteret.no/ (15.2.2019).
- 9.
Mega JL, Simon T, Collet JP et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010; 304: 1821–30. [PubMed][CrossRef]
- 10.
Holmes DR, Dehmer GJ, Kaul S et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2010; 56: 321–41. [PubMed][CrossRef]
- 11.
van der Wouden CH, Cambon-Thomsen A, Cecchin E et al. Implementing pharmacogenomics in Europe: Design and implementation strategy of the ubiquitous pharmacogenomics consortium. Clin Pharmacol Ther 2017; 101: 341–58. [PubMed][CrossRef]
- 12.
Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 2011; 89: 464–7. [PubMed][CrossRef]
- 13.
Dunnenberger HM, Crews KR, Hoffman JM et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol 2015; 55: 89–106. [PubMed][CrossRef]
- 14.
Moriyama B, Obeng AO, Barbarino J et al. (CPIC(R)) Guideline for CYP2C19 and voriconazole therapy. Clin Pharmacol Ther 2017; 102: 45–51. [PubMed][CrossRef]
- 15.
Hicks JK, Swen JJ, Thorn CF et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 2013; 93: 402–8. [PubMed][CrossRef]
- 16.
Caudle KE, Dunnenberger HM, Freimuth RR et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med 2017; 19: 215–23. [PubMed][CrossRef]
- 17.
Caudle KE, Keeling NJ, Klein TE et al. Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward. Pharmacogenomics 2018; 19: 847–60. [PubMed][CrossRef]
()
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.